FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients received enoxaparin sodium (4,000 IU (40 mg) subcutaneously) daily for 6 to 10 days and were then randomly assigned to receive either enoxaparin sodium or placebo for another 21 days.
Croatian: Bolesnici su primali enkosaparinnatrij (4000 IU [40 mg] supkutano) svakodnevno tijekom 6 do 10 dana, nakon čega su bili randomizirani za primanje enoksaparinnatrija ili placeba tijekom još 21 dana.
English: Subcutaneous injection technique
Croatian: Tehnika supkutanog injiciranja
English: • Proximal DVT (%) *p value versus placebo =0.008 #p value versus placebo =0.537
Croatian: • Proksimalni DVT (%) *p-vrijednost naspram placeba = 0,008 #p-vrijednost naspram placeba = 0,537
English: Inhixa 30,000 IU (300 mg)/3 mL solution for injection in multidose vial Inhixa 50,000 IU (500 mg)/5 mL solution for injection in multidose vial Inhixa 100,000 IU (1000 mg)/10 mL solution for injection in multidose vial enoxaparin sodium
Croatian: Inhixa 30 000 IU (300 mg)/3 ml otopina za injekciju u višedoznoj bočici Inhixa 50 000 IU (500 mg)/5 ml otopina za injekciju u višedoznoj bočici Inhixa 100 000 IU (1000 mg)/10 ml otopina za injekciju u višedoznoj bočici enoksaparinnatrij
English: Pregnant women with mechanical prosthetic heart valves The use of enoxaparin sodium for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves has not been adequately studied.
Croatian: Trudnice s mehaničkim umjetnim srčanim zaliscima Primjena enoksaparinnatrija za tromboprofilaksu u trudnica s mehaničkim umjetnim srčanim zaliscima nije adekvatno ispitana.
English: 100 IU/kg (1 mg/kg) body weight subcutaneously once daily
Croatian: 100 IU/kg (1 mg/kg) tjelesne težine supkutano jedanput na dan
English: For intravenous injection, either the multidose vial or pre-filled syringe can be used.
Croatian: Za intravensku se injekciju može upotrijebiti višedozna bočica ili napunjena štrcaljka.
English: When given at a dose of 4,000 IU (40 mg) once a day subcutaneously, enoxaparin sodium significantly reduced the incidence of VTE as compared to placebo.
Croatian: Kada se primjenjivao u dozi od 4000 IU (40 mg) supkutano jedanput na dan, enoksaparinnatrij je značajno snizio incidenciju VTE-a u odnosu na placebo.
English: Initiate dosing with 75 IU/kg (0.75 mg/kg) subcutaneously every 12 hours (maximum 7,500 IU (75 mg) for each of the first two subcutaneous doses only, followed by 75 IU/kg (0.75 mg/kg) subcutaneous dosing for the remaining doses).
Croatian: Primjenu treba započeti supkutanom dozom od 75 IU/kg (0,75 mg/kg) svakih 12 sati (najviše 7500 IU [75 mg] samo za svaku od prve dvije supkutane doze, nakon kojih se liječenje nastavlja supkutanim dozama od 75 IU/kg [0,75 mg/kg]).
English: See “Do not use Inhixa”.
Croatian: Pogledajte odlomak „Nemojte primjenjivati Inhixu”.
English: How to use Inhixa
Croatian: Kako primjenjivati Inhixu
English: To avoid the possible mixture of enoxaparin sodium with other drugs, the intravenous access chosen should be flushed with a sufficient amount of sodium chloride 9 mg/mL (0.9%) solution for infusion or glucose solution prior to and following the intravenous bolus administration of enoxaparin sodium to clear the port of drug.
Croatian: Da bi se izbjeglo potencijalno miješanje enoksaparinnatrija s drugim lijekovima, odabrani intravenski pristup treba isprati dostatnom količinom otopine natrijeva klorida od 9 mg/ml (0,9 %) za infuziju ili otopine glukoze prije i nakon intravenske bolusne primjene enoksaparinnatrija kako bi se uklonili tragovi lijekova s otvora intravenske linije (porta).
English: : such as haematoma, ecchymosis other than at injection site, wound haematoma, haematuria, epistaxis and gastro-intestinal haemorrhage.
Croatian: : kao što su: hematom, ekhimoza (osim na mjestu injiciranja), hematom oko rane, hematurija, epistaksa i gastrointestinalno krvarenje
English: All treated extended prophylaxis patients Total VTE (%)
Croatian: Svi liječeni bolesnici koji su primali produljenu profilaksu Ukupni VTE (%)
English: In a double blind multicentre, parallel group study, enoxaparin sodium 2,000 IU (20 mg) or 4,000 IU (40 mg) once a day subcutaneously was compared to placebo in the prophylaxis of DVT in medical patients with severely restricted mobility during acute illness (defined as walking distance of <10 meters for ≤3 days).
Croatian: U dvostruko slijepom, multicentričnom ispitivanju s paralelnim skupinama, enoksaparinnatrij u dozi od 2000 IU (20 mg) ili 4000 IU (40 mg) supkutano jedanput na dan uspoređivao se s placebom u profilaksi DVT-a u medikamentozno liječenih bolesnika s izuzetno ograničenom pokretljivošću tijekom akutne bolesti (što se definiralo kao duljina hodne pruge < 10 metara tijekom ≤ 3 dana).
English: The Inhixa pre-filled syringes are for single dose use only.
Croatian: Napunjene štrcaljke Inhixe namijenjene su samo za jednokratnu primjenu.
English: The rate of the 30 day composite endpoint of death, myocardial re-infarction or intracranial haemorrhage (a measure of net clinical benefit) was significantly lower (p < 0.0001) in the enoxaparin sodium group (10.1%) as compared to the heparin group (12.2%), representing a 17% relative risk reduction in favour of treatment with enoxaparin sodium.
Croatian: Stopa kompozitne mjere ishoda, koja je uključivala smrt, ponovljeni infarkt miokarda ili intrakranijalno krvarenje (mjerilo neto kliničke koristi), nakon 30 dana bila je značajno niža (p < 0,0001) u skupini koja je primala enoksaparinnatrij (10,1%) nego u onoj liječenoj heparinom (12,2%), što predstavlja smanjenje relativnog rizika za 17% u korist liječenja enoksaparinnatrijem.
English: Accidental overdose with enoxaparin sodium after intravenous, extracorporeal or subcutaneous administration may lead to haemorrhagic complications.
Croatian: Slučajno predoziranje enoksaparinnatrijem nakon intravenske, ekstrakorporalne ili supkutane primjene može dovesti do komplikacija u vidu krvarenja.
English: Enoxaparin sodium compared to unfractionated heparin significantly decreased the incidence of the primary end point, a composite of death from any cause or myocardial re-infarction in the first 30 days after randomization [9.9 percent in the enoxaparin sodium group, as compared with 12.0 percent in the unfractionated heparin group] with a 17 percent relative risk reduction (p < 0.001).
Croatian: U usporedbi s nefrakcioniranim heparinom, enoksaparinnatrij je značajno snizio incidenciju primarne mjere ishoda, koja je objedinjavala smrt zbog bilo kojeg uzroka ili ponovljeni infarkt miokarda unutar prvih 30 dana nakon randomizacije (9,9% u skupini koja je primala enoksaparinnatrij u usporedbi s 12,0% u skupini koja je primala nefrakcionirani heparin), uz smanjenje relativnog rizika za 17% (p < 0,001).
English: There was a significant treatment benefit of enoxaparin sodium, as compared with unfractionated heparin, in patients who underwent percutaneous coronary intervention within 30 days after randomization (23 percent reduction in relative risk) or who were treated medically (15 percent reduction in relative risk, p=0.27 for interaction).
Croatian: Primijećena je značajna terapijska korist enoksaparinnatrija u usporedbi s nefrakcioniranim heparinom u bolesnika podvrgnutih perkutanoj koronarnoj intervenciji unutar 30 dana nakon randomizacije (smanjenje relativnog rizika za 23%) ili medikamentoznom liječenju (smanjenje relativnog rizika za 15%; p = 0,27 za interakciju).
English: There was a significant treatment benefit of enoxaparin sodium, as compared with unfractionated heparin, in patients who underwent percutaneous coronary intervention within 30 days after randomization (23 percent reduction in relative risk) or who were treated medically (15 percent reduction in relative risk, p = 0.27 for interaction).
Croatian: Primijećena je značajna terapijska korist enoksaparinnatrija u usporedbi s nefrakcioniranim heparinom u bolesnika podvrgnutih perkutanoj koronarnoj intervenciji unutar 30 dana nakon randomizacije (smanjenje relativnog rizika za 23%) ili medikamentoznom liječenju (smanjenje relativnog rizika za 15%; p=0,27 za interakciju).
English: Moderate and mild renal impairment
Croatian: Umjereno i blago oštećenje funkcije bubrega
English: *p value versus placebo = 0.008
Croatian: *p vrijednost u odnosu na placebo = 0,0002
English: • Uncommon: Hepatocellular liver injury*
Croatian: • Manje često: hepatocelularno oštećenje jetre*
English: All Treated Extended Prophylaxis Patients Total VTE
Croatian: Svi liječeni bolesnici koji su primali produljenu profilaksu Ukupni VTE
English: For dosage in elderly patients with impaired kidney function, see below “renal impairment” and section 4.4.
Croatian: Za doziranje u starijih bolesnika s oštećenjem bubrežne funkcije vidjeti odlomak „Oštećenje funkcije bubrega” u nastavku i dio 4.4).
English: Solution for injection in multidose vial 5 vials
Croatian: otopina za injekciju u višedoznoj bočici 5 bočica
English: • For acute STEMI, treatment is to be initiated with a single intravenous bolus injection immediately followed by a subcutaneous injection.
Croatian: • Kod akutnog STEMI-ja, liječenje treba započeti jednokratnom intravenskom bolusnom injekcijom, nakon koje se odmah primjenjuje supkutana injekcija.
English: When non-weight adjusted dosing was administered, it was found after a single-subcutaneous 4,000 IU (40 mg) dose, that anti-Xa exposure is 52% higher in low-weight women (< 45 kg) and 27% higher in low-weight men (< 57 kg) when compared to normal weight control subjects (see section 4.4).
Croatian: Kod primjene doza koje nisu bile prilagođene prema tjelesnoj težini, nakon jednokratne supkutane doze od 4000 IU (40 mg) utvrđeno je da je izloženost anti-Xa aktivnosti bila 52% veća kod žena niske tjelesne težine (< 45 kg) i 27% veća kod muškaraca niske tjelesne težine (< 57 kg) u usporedbi s kontrolnim ispitanicima normalne tjelesne težine (vidjeti dio 4.4).
English: Intracranial haemorrhage, Retroperitoneal haemorrhage
Croatian: Manje često: intrakranijalno krvarenje, retroperitonejsk o krvarenje
English: Extended prophylaxis of DVT following cancer surgery A double-blind, multicentre trial, compared a four-week and a one-week regimen of enoxaparin sodium prophylaxis in terms of safety and efficacy in 332 patients undergoing elective surgery for abdominal or pelvic cancer.
Croatian: Produljena profilaksa DVT-a nakon onkološkog kirurškog zahvata Dvostruko slijepo, multicentrično ispitivanje uspoređivalo je sigurnost i djelotvornost četverotjednog i jednotjednog režima profilakse enoksaparinnatrijem u 332 bolesnika podvrgnuta elektivnom onkološkom kirurškom zahvatu u abdomenu ili zdjelici.
English: In treatment of DVT with or without PE, patients receiving enoxaparin sodium were treated with either a 100 IU/kg (1 mg/kg) subcutaneous dose every 12 hours or a 150 IU/kg (1.5 mg/kg) subcutaneous dose once a day.
Croatian: Kod liječenja DVT-a praćenog PE-om ili bez njega, bolesnici su primali enoksaparinnatrij u supkutanoj dozi od 100 IU/kg (1 mg/kg) svakih 12 sati ili u supkutanoj dozi od 150 IU/kg (1,5 mg/kg) jedanput na dan.
English: After repeated subcutaneous administration of the 100 IU/kg (1 mg/kg) twice daily regimen, the steady-state is reached from day 3 to 4 with mean exposure about 65% higher than after a single dose and mean maximum and trough anti-Xa activity levels of about 1.2 and 0.52 IU/mL, respectively.
Croatian: Nakon ponovljene supkutane primjene doze od 100 IU/kg (1 mg/kg) dvaput na dan, stanje dinamičke ravnoteže postiže se između 3. i 4. dana, uz srednju vrijednost izloženosti koja je približno 65% veća nego nakon jednokratne doze te srednju vrijednost najviše i najniže anti-Xa aktivnosti od približno 1,2 odnosno 0,52 IU/ml.
English: After repeated subcutaneous 150 IU/kg (1.5 mg/kg) once daily dosing, mean AUC of anti-Xa activity is marginally higher at steady state in obese healthy volunteers (BMI 30-48 kg/m2) compared to non-obese control subjects, while maximum plasma anti-Xa activity level is not increased.
Croatian: Nakon ponovljene primjene supkutane doze od 150 IU/kg (1,5 mg/kg) jedanput na dan, srednja vrijednost AUC-a anti-Xa aktivnosti u stanju dinamičke ravnoteže bila je neznatno viša u pretilih zdravih dobrovoljaca (ITM: 30-48 kg/m2) nego u nepretilih kontrolnih ispitanika, dok vršna plazmatska anti-Xa aktivnost nije bila povećana.
English: 6 pre-filled syringes
Croatian: 6 napunjenih štrcaljki
English: 50 pre-filled syringes
Croatian: 50 napunjenih štrcaljki
English: 30 pre-filled syringes
Croatian: 30 napunjenih štrcaljki
English: The enoxaparin sodium dose was 4,000 IU (40 mg) subcutaneously once daily for prophylaxis of deep vein thrombosis following surgery or in acutely ill medical patients with severely restricted mobility.
Croatian: Doza enoksaparinnatrija iznosila je 4000 IU (40 mg) supkutano jedanput na dan za profilaksu duboke venske tromboze nakon kirurškog zahvata ili u medikamentozno liječenih bolesnika s akutnom bolešću i izuzetno ograničenom pokretljivošću.
English: o For patients managed with PCI, if the last subcutaneous dose of enoxaparin sodium was given less than 8 hours before balloon inflation, no additional dosing is needed.
Croatian: o U bolesnika koji se podvrgavaju perkutanoj koronarnoj intervenciji, ako je posljednja supkutana doza enoksaparinnatrija primijenjena manje od 8 sati prije napuhavanja balona, nije potrebna dodatna doza.
English: 9) Drop the used syringe into the sharps container.
Croatian: 9) Odložite upotrijebljenu štrcaljku u spremnik za oštre predmete.
English: • For treatment of unstable angina and NSTEMI, the recommended dose of enoxaparin sodium is 100 IU/kg (1 mg/kg) every 12 hours by subcutaneous injection administered in combination with antiplatelet therapy.
Croatian: • Za liječenje nestabilne angine i NSTEMI-ja, preporučena doza enoksaparinnatrija je 100 IU/kg (1 mg/kg) svakih 12 sati supkutanom injekcijom, u kombinaciji s antitrombocitnom terapijom.
English: Changing from blood thinners called vitamin-K antagonists (e.g. warfarin) to Inhixa Stop taking the vitamin-K antagonist.
Croatian: Prelazak s lijekova za razrjeđivanje krvi koji se zovu antagonisti vitamina K (npr. varfarin) na Inhixu Prestanite uzimati antagonist vitamina K.
English: Each mL contains 150 mg enoxaparin sodium.
Croatian: Jedan ml sadrži 150 mg enoksaparinnatrija.
English: Then, the required volume of diluted solution should be withdrawn with a syringe for administration into the intravenous line.
Croatian: Zatim štrcaljkom izvući potreban volumen razrijeđene otopine za primjenu u intravensku liniju.
English: 10) Drop the used syringe into the sharps container.
Croatian: 10) Odložite upotrijebljenu štrcaljku u spremnik za oštre predmete.
English: Enoxaparin sodium 150 IU/kg (1.5 mg/kg) once a day subcutaneously n (%)
Croatian: Enoksaparinnatrij 150 IU/kg (1,5 mg/kg) jedanput na dan supkutano n (%)
English: This medicine contains less than 1 mmol sodium (23 mg) per dose within the recommended dose range, that is to say essentially ‘sodium-free'.
Croatian: Ovaj lijek sadrži manje od 1 mmol natrija (23 mg) po dozi unutar preporučenog raspona doza, tj. zanemarive količine natrija.
English: How to store Inhixa
Croatian: Kako čuvati Inhixu
English: If a manual compression method is used, sheath should be removed 6 hours after the last intravenous/ subcutaneous enoxaparin sodium injection.
Croatian: Ako se provodi ručna kompresija, uvodnicu treba ukloniti 6 sati nakon posljednje intravenske/supkutane injekcije enoksparinnatrija.
English: Vascular disorders o Rare: Spinal haematoma* (or neuraxial haematoma).
Croatian: Krvožilni poremećaji o Rijetko: hematom kralježnice* (ili neuraksijalni hematom).
English: Enoxaparin sodium, as with any other anticoagulant therapy, should be used with caution in conditions with increased potential for bleeding, such as: - impaired haemostasis, - history of peptic ulcer, - recent ischemic stroke, - severe arterial hypertension, - recent diabetic retinopathy, - neuro- or ophthalmologic surgery, - concomitant use of medicinal products affecting haemostasis (see section 4.5).
Croatian: Kao i svaki drugi antikoagulans, enoksaparinnatrij mora se primjenjivati uz oprez kod stanja kod kojih postoji povećan rizik od krvarenja, kao što su: - poremećaj hemostaze - peptički ulkus u anamnezi - nedavno pretrpljen ishemijski moždani udar - teška arterijska hipertenzija - nedavna dijabetička retinopatija - neurološki ili oftalmološki kirurški zahvat - istodobna primjena lijekova koji utječu na hemostazu (vidjeti dio 4.5)
English: Benzyl alcohol Water for injections
Croatian: 6.1 Popis pomoćnih tvari Benzilni alkohol Voda za injekcije
English: In patients with severe renal impairment (creatinine clearance < 30 mL/min), the AUC at steady state is significantly increased on average by 65% after repeated subcutaneous 4,000 IU (40 mg) once daily doses (see sections 4.2 and 4.4).
Croatian: U bolesnika s teškim oštećenjem bubrežne funkcije (klirens kreatinina < 30 ml/min), AUC u stanju dinamičke ravnoteže značajno je povišen za prosječno 65% nakon ponovljene supkutane primjene doze od 4000 IU (40 mg) jedanput na dan (vidjeti dijelove 4.4 i 4.2).
English: Inhixa 12,000 IU (120 mg)/0.8 mL solution for injection Inhixa 15,000 IU (150 mg)/1 mL solution for injection enoxaparin sodium
Croatian: Inhixa 12 000 IU (120 mg)/0,8 ml otopina za injekciju Inhixa 15 000 IU (150 mg)/1 ml otopina za injekciju enoksaparinnatrij
English: Illness
Croatian: Liječenje
English: Prophylaxis of venous thromboembolism in medical patients The recommended dose of enoxaparin sodium is 4,000 IU (40 mg) once daily by subcutaneous injection.
Croatian: Profilaksa venske tromboembolije u medikamentozno liječenih bolesnika Preporučena doza enoksaparinnatrija je 4000 IU (40 mg) jedanput na dan supkutanom injekcijom.
English: Enoxaparin sodium 100 IU/kg (1 mg/kg) twice a day subcutaneously n (%)
Croatian: Enoksaparinnatrij 100 IU/kg (1 mg/kg) dvaput na dan supkutano n (%)
English: History of HIT (> 100 days)
Croatian: Heparinom izazvana trombocitopenija (HIT) u anamnezi (> 100 dana)
English: Sodium content This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free'.
Croatian: Sadržaj natrija Ovaj lijek sadrži manje od 1 mmol natrija (23 mg) po dozi, tj. zanemarive količine natrija.
English: • In patients at moderate risk of thromboembolism, the recommended dose of enoxaparin sodium is 2,000 IU (20 mg) once daily by subcutaneous injection.
Croatian: • U bolesnika s umjerenim rizikom od tromboembolije preporučena doza enoksaparinnatrija je 2000 IU (20 mg) jedanput na dan supkutanom injekcijom.
English: Common:
Croatian: NN:
English: • For treatment of acute STEMI, the recommended dose of enoxaparin sodium is a single intravenous bolus of 3,000 IU (30 mg) plus a 100 IU/kg (1 mg/kg) subcutaneous dose followed by 100 IU/kg (1 mg/kg) administered subcutaneously every 12 hours (maximum 10,000 IU (100 mg) for each of the first two subcutaneous doses).
Croatian: • Za liječenje akutnog STEMI-ja, preporučena doza enoksaparinnatrija je jednokratni intravenski bolus od 3000 IU (30 mg) plus supkutana doza od 100 IU/kg (1 mg/kg), nakon koje slijedi supkutana primjena doze od 100 IU/kg (1 mg/kg) svakih 12 sati (najviše 10 000 IU (100 mg) za svaku od prve dvije supkutane doze).
English: When the quantity of drug to be injected requires to be adjusted based on the patient's body weight, the graduated pre-filled syringes should be used to reach the required volume by discarding the excess before injection.
Croatian: Kada se količina lijeka koja će se injicirati treba prilagoditi prema tjelesnoj težini bolesnika, potrebno je upotrijebiti graduiranu napunjenu štrcaljku i prilagoditi volumen izbacivanjem viška prije injekcije.
English: All Treated Medical
Croatian: NAČIN PRIMJENE LIJEKA
English: An increase in exposure of enoxaparin sodium with prophylactic dosages (non-weight adjusted) has been observed in low-weight women (< 45 kg) and low-weight men (< 57 kg), which may lead to a higher risk of bleeding.
Croatian: U žena i muškaraca niske tjelesne težine (< 45 kg odnosno < 57 kg) primijećeno je povećanje izloženosti enoksaparinnatriju u profilaktičkim dozama (neprilagođenima tjelesnoj težini), koje može povećati rizik od krvarenja.
English: To avoid the possible mixture of enoxaparin sodium with other drugs, the intravenous access chosen should be flushed with a sufficient amount of sodium chloride or dextrose solution prior to and following the intravenous bolus administration of enoxaparin sodium to clear the port of drug.
Croatian: Da bi se izbjeglo potencijalno miješanje enoksaparinnatrija s drugim lijekovima, odabrani intravenski pristup treba isprati dostatnom količinom otopine natrijeva klorida ili glukoze prije i nakon intravenske bolusne primjene enoksaparinnatrija kako bi se uklonili tragovi lijekova s otvora intravenske linije (porta).
English: • In patients at high risk of thromboembolism, the recommended dose of enoxaparin sodium is 4,000 IU (40 mg) once daily given by subcutaneous injection preferably started 12 hours before surgery.
Croatian: • U bolesnika s visokim rizikom od tromboembolije preporučena doza enoksaparinnatrija je 4000 IU (40 mg) jedanput na dan supkutanom injekcijom, a primjenu bi po mogućnosti trebalo započeti 12 sati prije operacije.
English: Benzyl alcohol (75 mg in 5.0 mL)
Croatian: Pomoćna(e) tvar(i) s poznatim učinkom Benzilni alkohol (75 mg u 5,0 ml)
English: In patients with severe renal impairment (creatinine clearance 15-30 mL/min), since exposure of enoxaparin sodium is significantly increased, a dosage adjustment is recommended for therapeutic and prophylactic dosage ranges (see section 4.2).
Croatian: Zbog značajno povećane izloženosti enoksaparinnatriju u bolesnika s teškim oštećenjem bubrežne funkcije (klirens kreatinina: 15-30 ml/min), preporučuje se prilagoditi doze u terapijskom i profilaktičkom rasponu (vidjeti dio 4.2).
English: Similar to the first study the incidence of VTE during extended prophylaxis was significantly lower for enoxaparin sodium compared to placebo for both total VTE (enoxaparin sodium 21 [16%] versus placebo 45 [34.4%]; p = 0.001) and proximal DVT (enoxaparin sodium 8 [6.1%] versus placebo 28 [21.4%]; p =< 0.001).
Croatian: Slično kao i u prvom ispitivanju, incidencija VTE-a tijekom produljene profilakse bila je značajno niža uz enoksaparinnatrij nego uz placebo i za ukupni VTE (21 uz enoksaparinnatrij [16%] naspram 45 uz placebo [34,4%]; p = 0,001) i za proksimalni DVT (8 uz enoksaparinnatrij [6,1%] naspram 28 uz placebo [21,4%]; p =< 0,001).
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Croatian: PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE VIŠEDOZNE BOČICE
English: *p value versus placebo =0.008 #p value versus placebo =0.537
Croatian: *p-vrijednost naspram placeba = 0,008 #p-vrijednost naspram placeba = 0,537
English: Mechanical prosthetic heart valves
Croatian: Mehanički umjetni srčani zalisci
English: Instructions on injecting yourself with Inhixa
Croatian: Upute kako samoinjicirati Inhixu
English: Enoxaparin sodium pharmacokinetics appeared similar than control population, after a single 25 IU, 50 IU or 100 IU/kg (0.25, 0.50 or 1.0 mg/kg) intravenous dose however, AUC was two-fold higher than control.
Croatian: Nakon jednokratne intravenske doze od 25 IU (0,25 mg/kg), 50 IU (0,50 mg/kg) ili 100 IU/kg (1,0 mg/kg), farmakokinetika enoksaparinnatrija činila se sličnom onoj u kontrolnoj skupini, ali je AUC bio dvostruko viši nego u kontrolnoj skupini.
English: 1 x 3,000 IU (30 mg) intravenous bolus plus 100 IU/kg (1 mg/kg) body weight subcutaneously and then 100 IU/kg (1 mg/kg) body weight subcutaneously every 24 hours No intravenous initial bolus, 100 IU/kg (1 mg/kg) body weight subcutaneously and then 100 IU/kg (1 mg/kg) body weight subcutaneously every 24 hours
Croatian: 1 x 3000 IU (30 mg) intravenskim bolusom plus 100 IU/kg (1 mg/kg) tjelesne težine supkutano, a zatim 100 IU/kg (1 mg/kg) tjelesne težine supkutano svaka 24 sata Bez početne intravenske bolusne doze, 100 IU/kg (1 mg/kg) tjelesne težine supkutano, a zatim 100 IU/kg (1 mg/kg) tjelesne težine supkutano svaka 24 sata